CEO (Gene Therapy) - Remote from Europe

CEO (Gene Therapy) - Remote from Europe

CEO (Gene Therapy) - Remote from Europe

Location : Remote Commitment : ~80% (approximately) Compensation : Primarily equity-based, modest base salary until fundraising. Start Date : ASAP preferred, Q1 2026 the latest. Seniority : Founder / leadership

About the Venture (XtRNA Bio)

XtRNA Bio is a pioneering biotechnology company redefining how we treat rare genetic diseases through transfer RNA (tRNA) therapeutics. Originating from groundbreaking research at Radboud University and founded in collaboration with NLC Health Ventures, XtRNA Bio is translating cutting-edge RNA biology into a new class of medicines that repair disease at its molecular root.

The lead program targets Charcot-Marie-Tooth disease type 2D (CMT2D), a severe neuromuscular disorder caused by mutations in the GARS1 gene. These mutations interfere with how motor neurons use tRNAs to make essential proteins, leading to progressive nerve damage. XtRNA Bio's AAV-mediated tRNA therapy restores normal protein synthesis, directly addressing the underlying cause of disease. Preclinical studies have demonstrated strong proof of concept, showing potential to halt or even reverse neurodegeneration.

While CMT2D is the initial focus, the tRNA platform has broad potential. Through two complementary approaches, elevating disease-relevant tRNAs and engineering suppressor tRNAs for nonsense mutations, it can target a wide range of genetic diseases caused by translational errors. This dual-modality approach places us among a select few companies globally advancing tRNA as a therapeutic modality.

Supported by non-dilutive funding from the CMT Research Foundation and collaborations with world-leading scientists in the Netherlands and Germany, XtRNA Bio is now advancing toward IND-enabling studies. With strong science, early validation, and a mission-driven culture, XtRNA is building a biotech platform poised to transform RNA medicine, and bring new hope to patients with currently untreatable genetic diseases.

Purpose of the Role

The CEO of XtRNA Bio will lead the company's mission to transform advanced RNA science into therapies for rare genetic diseases. You will guide the venture from research to clinical development, shape its strategy, and drive the fundraising needed to achieve key milestones.

This role calls for a leader who can unite scientific vision with business execution. You will inspire a high-performing team, build strategic partnerships, attract investors, and position XtRNA Bio as a pioneering force in RNA medicine.

Responsibilities (XtRNA Bio)

As CEO of XtRNA Bio, you will provide strategic and operational leadership to advance our pioneering tRNA therapeutic platform from research toward clinical development. Key responsibilities include :

• Lead the company's overall strategy, growth, and fundraising, securing seed and Series A investment
• Drive the scientific and clinical roadmap in collaboration with the CSO toward IND readiness for the CMT2D program while expanding the broader tRNA platform
• Build and inspire a multidisciplinary team that combines scientific excellence with entrepreneurial focus
• Establish strong partnerships with investors, academic collaborators, pharmaceutical partners, and patient foundations
• Represent XtRNA Bio externally, communicating our vision, progress, and potential to the biotech and investment communities

This role calls for a leader who can unite scientific insight, strategic execution, and purpose-driven leadership to position XtRNA Bio at the forefront of RNA-based medicine.

Requirements (XtRNA Bio)

To succeed as CEO of XtRNA Bio, you will bring a rare combination of scientific understanding, strategic leadership, and entrepreneurial drive.

Qualifications

If you are driven by the opportunity to transform pioneering RNA science into therapies that change lives, we invite you to shape the future of XtRNA Bio with us.

About NLC

NLC Health Ventures is a leading healthtech and biotech innovation platform based in Amsterdam, combining venture building and fund management across Europe and North America. With 40-45 employees, NLC manages four captive funds investing in ventures from pre-seed to Series B-C, and is fundraising for a fifth fund. The funds have a diverse LP base and are invested in over 70 companies. NLC values a collaborative, open, and impact-driven culture, where team members' ideas and contributions truly matter.